Cysteamine-bicalutamide combination therapy corrects proximal tubule phenotype in cystinosis

Amer Jamalpoor, Charlotte Agh van Gelder, Fjodor A Yousef Yengej, Esther A Zaal, Sante P Berlingerio, Koenraad R Veys, Carla Pou Casellas, Koen Voskuil, Khaled Essa, Carola Me Ammerlaan, Laura Rita Rega, Reini En van der Welle, Marc R Lilien, Maarten B Rookmaaker, Hans Clevers, Judith Klumperman, Elena Levtchenko, Celia R Berkers, Marianne C Verhaar, Maarten AltelaarRosalinde Masereeuw, Manoe J Janssen

Onderzoeksoutput: Bijdrage aan wetenschappelijk tijdschrift/periodieke uitgaveArtikelWetenschappelijkpeer review

Samenvatting

Nephropathic cystinosis is a severe monogenic kidney disorder caused by mutations in CTNS, encoding the lysosomal transporter cystinosin, resulting in lysosomal cystine accumulation. The sole treatment, cysteamine, slows down the disease progression, but does not correct the established renal proximal tubulopathy. Here, we developed a new therapeutic strategy by applying omics to expand our knowledge on the complexity of the disease and prioritize drug targets in cystinosis. We identified alpha-ketoglutarate as a potential metabolite to bridge cystinosin loss to autophagy, apoptosis and kidney proximal tubule impairment in cystinosis. This insight combined with a drug screen revealed a bicalutamide-cysteamine combination treatment as a novel dual-target pharmacological approach for the phenotypical correction of cystinotic kidney proximal tubule cells, patient-derived kidney tubuloids and cystinotic zebrafish.

Originele taal-2Engels
Pagina's (van-tot)e13067
TijdschriftEMBO Molecular Medicine
Volume13
Nummer van het tijdschrift7
DOI's
StatusGepubliceerd - 07 jul. 2021

Vingerafdruk

Duik in de onderzoeksthema's van 'Cysteamine-bicalutamide combination therapy corrects proximal tubule phenotype in cystinosis'. Samen vormen ze een unieke vingerafdruk.

Citeer dit